TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16374158
Drug: Short-stay intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-stay intensive care (SSIC) treatment (8 hrs of intensive care treatment)
Study: 14635284
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg twice a day of celecoxib
Study: 14635284
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice a day of celecoxib
Study: 14635284
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice a day of celecoxib
Study: 14635284
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice a day of naproxen
Study: 3899029
Drug: Immunotherapy (Levamisole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (Levamisole and Intrapleural BCG)
Study: 3899029
Drug: Chemotherapy (CisPlatinum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CisPlatinum, Adriamycin, and Cytoxan)
Study: 27871565
Drug: Periarticular drug
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular drug injection
Study: 29121334
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dronabinol
Study: 16710114
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dronabinol
Study: 22511794
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion in thyroidectomized patients
Study: 22511794
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion in healthy volunteers
Study: 20122281
Drug: Supervised, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised, twice weekly exercise training with regular review of airway clearance therapy
Study: 20122281
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly telephone support
Study: 15753114
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin on alternate days
Study: 12897285
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose indomethacin (0.2 mg/kg/dose every 12 hours for 3 doses)
Study: 12897285
Drug: Prolonged low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged low-dose indomethacin (0.1 mg/kg/dose daily for 6 doses)
Study: 12897285
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose indomethacin
Study: 12897285
Drug: Prolonged low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged low-dose indomethacin
Study: 1851339
Drug: VACE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACE regimen (vincristine 1.2 mg/m2, doxorubicin 40 mg/m2, cyclophosphamide 700 mg/m2 on day 1 plus etoposide 110 mg/m2 daily for three days)
Study: 1851339
Drug: CVACE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVACE regimen (identical to VACE for cycles 3 and 4; cycles 1, 2, 4, and 6 consisted of etoposide 110 mg/m2 for three days plus cisplatin 100 mg/m2 with mannitol diuresis on the second day)
Study: 6119097
Drug: Cloxazolam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxazolam (3 mg)
Study: 18762476
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin (100 mg daily)
Study: 31550962
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) plus low dose aspirin (40 mg enoxaparin and 100 mg aspirin daily)
Study: 31550962
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) alone (40 mg enoxaparin daily)
Study: 11309635
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg or 120 mg)
Study: 8557525
Drug: Isoniazid tablets
Normalized name: Isoniazid Tablets
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid tablets plus pyridoxin tablets once a day for 30 days
Study: 2796626
Drug: Intravenous lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lidocaine, 1 mg/kg
Study: 31176632
Drug: AP‐CD/LD (50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP‐CD/LD (50/250 mg, 50/375 mg, or 50/500 mg)
Study: 27986606
Drug: S-ketamine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (bolus of 0.11mg/kg, followed by a maintenance infusion of 0.12mg/kg)
Study: 7988776
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl infusion)
Study: 24913571
Drug: Erythropoietin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (total dose of about 40,000 U)
Study: 22386829
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg and Amlodipine 10 mg (T/A)
Study: 9066353
Drug: Cerebrospinal fluid/serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid/serum ratios for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Study: 9066353
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels for soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1
Study: 8410217
Drug: Methylprednisolone (very
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (very high doses) administered within 8 hours of injury
Study: 8410217
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with methylprednisolone
Study: 22500386
Drug: Danning Tablet
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danning Tablet
Study: 20573778
Drug: Thiazide-like diuretic
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-like diuretic (indapamide 1.5 mg SR) + ACE inhibitor (perindopril 2-4 mg)
Study: 17646516
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 2 mg
Study: 17646516
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 4 mg
Study: 17646516
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 7 mg
Study: 17646516
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 10 mg
Study: 17646516
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 14 mg
Study: 17136950
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg daily for 6 weeks
Study: 11995818
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with six i.v. infusions of fotémustine
Study: 10446490
Drug: KRN8602 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRN8602 (15 mg/m2/day for 5 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Study: 10446490
Drug: Daunorubicin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin (40 mg/m2/day for 3 days) + Cytosine arabinoside (100 mg/m2/day for 7 days)
Study: 7493059
Drug: Oxygent® (1.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygent® (1.35 g PFC/kg)
Study: 7493059
Drug: Oxygent® (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygent® (1.8 g PFC/kg)
Study: 7471802
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream (0.025%)
Study: 7471802
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream (0.025%) and Placebo cream
Study: 31961926
Drug: Obinutuzumab-based chemotherapy
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab-based chemotherapy induction
Study: 31961926
Drug: Rituximab-based chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-based chemotherapy induction
Study: 24576148
Drug: PSYMEPHY treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSYMEPHY treatment (6-week interdisciplinary treatment)
Study: 22860637
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg AA
Study: 22860637
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg AA
Study: 22860637
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg AA
Study: 17516992
Drug: CoQ(10) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 45 days (Group IV)
Study: 17516992
Drug: CoQ(10) 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ(10) 100 mg, riboflavin 10 mg, niacin 50 mg along with tamoxifen 10 mg twice a day for 90 days (Group V)
Study: 17516992
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice a day for more than 1 year (Group III)
Study: 15498622
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg/d, at least one i.v. dose)
Study: 11465936
Drug: alpha-tocopherol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-tocopherol (500 mg b.i.d.)
Study: 2916871
Drug: Clonidine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (initial dose of 0.1 mg with hourly doses of 0.1 mg)
Study: 30412905
Drug: Glucose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (75 g, GLU) alone
Study: 24725465
Drug: PCA with
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA with remifentanil and diclofenac (50 mg)
Study: 24725465
Drug: Pethidine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (2 mg/kg i.m.) and midazolam (7.5 mg)
Study: 14596626
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral contraceptive (Estrostep, containing norethisterone acetate 1mg and ethinylestradiol [20, 30, 35 mg])
Study: 11024603
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1 mg kg(‐1) bolus followed by 40 microg kg(‐1) min(‐1) for 4 hours)
Study: 1307344
Drug: Conventional intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intramuscular analgesia
Study: 29420518
Drug: Gabapentin 450
Normalized name: gabapentin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 450 mg
Study: 22317944
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (200 mg and 400 mg respectively)
Study: 22317944
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg) and placebo
Study: 22317944
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg) and placebo
Study: 20183736
Drug: Hypnosis/therapeutic suggestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnosis/therapeutic suggestion with standard sedation dose of intravenous anesthetic
Study: 18568696
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment based on home BP monitoring
Study: 12523216
Drug: Probiotics for
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics for systemic diseases (e.g., atopic dermatitis)
Study: 6111330
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 80 mg (single dose)
Study: 6111330
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 80 mg (2 weeks administration, twice daily)
Study: 6111330
Drug: Intravenous propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propranolol (0.2 mg/kg)
Study: 6111330
Drug: Intravenous practolol
Normalized name: practolol
DrugBank: Practolol (DB01297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous practolol (1 mg/kg)
Study: 6111330
Drug: Intravenous atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atenolol (0.2 mg/kg)
Study: 6111330
Drug: Intravenous SL
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous SL 75212 (0.15 and 0.6 mg/kg)
Study: 6111330
Drug: Propranolol 100
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 100 and 500 μg/ml added to whole blood
Study: 6111330
Drug: Lignocaine 5
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 5 μg/ml added to whole blood
Study: 6111330
Drug: Propranolol at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol at 1000 ng/ml or less
Study: 6111330
Drug: Sotalol 5
Normalized name: SOTALOL 5MG/ML ORAL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol 5 and 500 μg/ml and 5 mg/ml
Study: 30793920
Drug: ¼ dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: ¼ dose reduction fluoroscopy
Study: 28202072
Drug: Mini implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini implants (MI)
Study: 28202072
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants (CI)
Study: 25823790
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg spironolactone (MR availability)
Study: 19577021
Drug: Salbutamol (sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)
Study: 17038059
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction Power (CAPB) with three different modes of brushing
Study: 14642054
Drug: Medication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication treatment alone
Study: 9308061
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion anaesthesia
Study: 23318497
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with Acipimox (Aci) administration
Study: 23318497
Drug: Acipimox (Aci)
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (Aci) administration post-exercise
Study: 18259012
Drug: Norepinephrine transporter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine transporter inhibition with 8 mg reboxetine
Study: 17020983
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (175 mg/m(2)/i.v.)
Study: 15284389
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (S) - 26.6 +/- 4.5 g protein, 44.4 +/- 7.5 mg isoflavones/d
Study: 15284389
Drug: Soy +
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy + probiotics (S+P) - 10(9) colony-forming units Lactobacillus acidophilus DDS+1 and Bifidobacterium longum, 15-30 mg fructooligosaccharide/d
Study: 15284389
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (M) - 26.6 +/- 4.5 g protein/d
Study: 10197170
Drug: Synovial fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synovial fluid markers (aggrecan fragments, matrix metalloproteinases-1 and -3, tissue inhibitor of metalloproteinases-1)
Study: 3277506
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (2 g in 60 mL nightly retention enema for 8 weeks)
Study: 3277506
Drug: Placebo (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (60 mL nightly retention enema for 8 weeks)
Study: 28817199
Drug: Biological products
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological products for the treatment of rheumatoid arthritis
Study: 26225130
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration (PLA)
Study: 24188672
Drug: Immunotherapy (M-FP)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (M-FP)
Study: 21344046
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention of CBT for insomnia and imagery rehearsal therapy
Study: 21041921
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg twice daily
Study: 21150563
Drug: etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: etravirine 400 mg once daily
Study: 18445705
Drug: moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin 400 mg once daily (positive control)
Study: 16480472
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (20 microg) added to hyperbaric bupivacaine (2.0 ml of 0.5%)
Study: 16480472
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine (2.0 ml of 0.5%) with saline (0.4 ml)
Study: 9093498
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy from a trained community nurse
Study: 9093498
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual from general practitioner
Study: 8458463
Drug: 7-day protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day protocol (Tripteriline 0.1, administered daily for 7 days starting on cycle day 2)
Study: 8458463
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol (Tripteriline 3.75 mg, administered on cycle day 2)
Study: 2427857
Drug: Celiprolol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (0.07 and 0.14 mg/kg)
Study: 2427857
Drug: Propranolol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.07 mg/kg)
Study: 27502721
Drug: Full (unadjusted)
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full (unadjusted) dose of chemotherapy
Study: 27502721
Drug: Adjusted BSA
Normalized name: Fmlt bsasm h
DrugBank: Honokiol (DB19283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted BSA chemotherapy
Study: 27502721
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients receiving full-dose chemotherapy
Study: 27502721
Drug: Obese patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obese patients receiving adjusted BSA chemotherapy
Study: 24060107
Drug: tDCS combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS combined with sertraline
Study: 19747986
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with PEG interferon alfa-2b 3.0 mcg/kg/wk for 12 weeks followed by PEG interferon alfa-2b 1.5 mcg/kg/wk for 36 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Study: 19747986
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) with PEG interferon alfa-2b 1.5 mcg/kg weekly for 48 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Study: 19747986
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy in patients weighing more than 85 kg
Study: 15950851
Drug: Droperidol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (50 mug) with morphine (1 mg) via PCA
Study: 15950851
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mg morphine via PCA)
Study: 12730085
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol (E2) 50 microg (tE2 group, n=33)
Study: 12730085
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 1 mg (oE2 group, n=37)
Study: 12730085
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 1 mg combined with gestodene 25 microg (oE2+G group, n=33)
Study: 10493334
Drug: PNCRM7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCRM7 vaccine
Study: 10493334
Drug: PNCRM7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCRM7 vaccine with hepatitis B vaccine
Study: 10493334
Drug: PNCRM7 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNCRM7 vaccine with DTaP and HbOC
Study: 24131861
Drug: Enhanced cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced cognitive behaviour therapy
Study: 24131861
Drug: Optimised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised treatment as usual
Study: 29567358
Drug: Topical VTP‐38543
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical VTP‐38543 (0.05%, 0.15%, and 1.0%) applied twice daily for 28 days
Study: 26611780
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (n = 55) ingested daily 9 log10 colony‐forming units of L. salivarius PS2 from approximately week 30 of pregnancy until delivery